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Abbreviations
AR: Androgen receptor
ARBS3.12: AR binding site on chromosome 3 
ARE: Androgen response element
CBP: calmoduline binding peptide
CDK4: Cyclin dependent kinase 4
ChIP: Chromatin immunoprecipitation
CYR61: Cysteine-rich, angiogenic inducer, 61
DNA: Deoxyribonucleic acid
ELL2: elongation factor, RNA polymerase II
FKBP5: FK506 binding protein 5
GAPDH: Glyceraldehyde 3 phosphate dehydrogenase
HDAC3: Histone deacetylase 3
HPV18: Human papillomavirus 18
mRNA: Messenger ribonucleic acid
NCoR: Nuclear receptor co-repressor
NEP: Neutral endopeptidase
NKX3.1: NK3 homeobox 1
PC: Prostate cancer
SBP: Streptavidine binding peptide
shRNA: Small hairpin RNA
SGK: Serum glucocorticoid kinase
XBP: X box binding protein
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Abstract
In this work we have studied the mechanisms of regulation of expression of androgen receptor
(AR) target genes. We have used an immortalized non-tumorigenic prostate cell line RWPE-
1-ARtag constitutively expressing an exogenous AR as a model. We observed that all studied
AR target genes exhibited a specific expression during the G1 phase of the cell cycle despite
the constitutive expression of AR. Importantly, we found that the expression of NCoR, an AR
corepressor, was downregulated during the G1 phase and expressed as mRNA and protein
specifically during the S phase. The role of NCoR in repressing androgen-induced expression
of AR target genes in S phase was further demonstrated by altering expression of NCoR
during the cell cycle through knock down or induced overexpression. Using two alternative
techniques we show that AR binds directly to target DNA in the chromatin only during the G1
phase. These data support the hypothesis that NCoR might control a cell cycle dependent
regulation of expression AR target genes in prostate cells. 
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1.  Introduction
Androgen receptor (AR) belongs to the nuclear receptor superfamily. It is a ligand-
dependent transcription factor that directly controls transcription of target genes through the
binding to specific Androgen responsive Elements (ARE) within the genome. In men AR is
essential for both sexual differentiation and prostate development. On the other hand AR is
also implicated in several prostatic diseases including prostate cancer (PC). Prostate cancer is
the most common cancer among men in Western countries [1]. Androgens activate cell
proliferation at the very early stages of tumor development. The role of AR in PC
development has been widely documented and regulation of AR target genes expression is
found deeply altered in many cases of advanced cancer. Androgen suppression therapies can
abrogate tumor cell proliferation, however in advanced stages and in metastatic forms of PC,
uncontrolled proliferation becomes independent of androgen signaling due to altered AR
signaling pathway. In some cases anti-androgen compounds can even activate cell
proliferation [2-6]. To explain these phenomena several molecular mechanisms have been
proposed including hypersensitivity to androgens due to amplification of genes encoding AR
or AR co-activators, mutations in AR or co-factors inducing constitutive transcriptional
activation of AR target genes, altered cross talks with other signaling pathways. In some cases
alterations of AR function results from chromosome rearrangements, etc. [6,7]. Recent
studies proposed AR as a licensing factor for DNA replication in prostate cancer cells [8,9].
Therefore, it is of crucial importance to understand the molecular mechanisms through which
AR regulates target gene transcription in prostate cells and controls thereby cell proliferation.
The activity of nuclear receptors in general, and of AR in particular, is controlled
through interaction with co-activators and co-repressors [10]. Co-activators and co-repressors
are able to induce alterations in chromatin structure through posttranslational modifications of
4
Page 5 of 44
Ac
ce
pte
d M
an
us
cri
pt
the core histone amino-termini. Among co-repressors NCoR is a high molecular multiprotein
complex that comprises seven different subunits. The only identified partner of NCoR that
shows an enzymatic (deacetylase) activity is HDAC3 [11]. The mechanisms of action of
NCoR were recently reviewed [12]. 
In this work we aimed at deciphering the mechanisms governing AR accessibility to
control regions of target genes in the nucleus and the regulation of AR target gene expression
in a model of non-tumor prostate cells. We observed that in these cells AR target genes are
expressed only during the G1 phase of the cell cycle in response to androgen stimulation. We
show that NCoR is expressed only during the S and G2-M phases of the cell cycle and further
demonstrate that this cell cycle dependent expression of NCoR is responsible of the non-
productive binding of AR to the promoter of target genes during these phases. The interaction
of NCoR and AR has already been described. However, this interaction was shown to be
further stabilized by the treatment with AR antagonists such as bicatulimide or mifepristone
[13,14]. Our experiments show a new link between AR and NCoR in absence of drug
treatment, i.e. in more physiologic conditions. Our data also identify then the cell cycle
regulated expression of NCoR as a key factor in the control of cyclic expression of androgen
responsive genes.
2. Materials and Methods
2.1.Vectors and cells
The human cDNA of AR was cloned in the pCTAP vector (Stratagene 240102) to
produce an AR tagged on C-terminal by the streptavidin binding peptide (SBP) and the
calmodulin binding peptide (CBP). This ARtag was cloned into a viral vector, pWRIR, derived
from HIV. Construction and production of viral vectors and isolation of infected cells were
performed in collaboration with Dr. D. Nègre (vectorology facility, IFR Biosciences Gerland
5
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Lyon Sud, Lyon, France). In this vector the ARtag is transcribed from an internal EF2
promoter. This vector also contains a GFP sequence transcribed from the same EF2 promoter
and translated via an IRES sequence. Helper free vector particles were produced trough
transfection of the pWRIR-AR DNA into the transcomplementing MCF-7 cells. RWPE-1-
ARtag cells were obtained by infecting RWPE-1 cells with helper free pWRIR-AR particles.
The tagging AR did not change its ability to translocate into the nucleus (figure 1 D). As
compared to wtAR the tagged form showed the same functional response curve to increasing
concentrations of a reporting ARE construct in transient transfection showing that the
transcriptional efficiency was not altered (data not shown). Infection conditions were
determined to have no more than 2 particles per cell (multiplicity of infection, MOI=2). GFP
positive cells were sorted out by flow cytometry and cloned by single cell seeding into 96-well
plates. Cells were maintained in keratinocyte growth medium (Invitrogen 17005-042)
supplemented with rEGF (recombinant epithelial growth factor) and BPE (bovine pituary
extract) (Invitrogen 37000015), antibiotics and antimycotics. RWPE-1-ARtag cells were
stimulated with 1nM of R1881, a non-metabolisable androgen, in the growth medium
deprived of BPE. R1881 was prepared as an ethanol stock solution and diluted in the growth
medium.  Non-stimulated cells were treated with diluted ethanol as vehicle.
Human lentiviral NCoR shRNA (036SC-36001V) and Scramble shRNA (036SC-
108080) particles were bought from TebuBio. MOI was determined using lentiviral copGFP
particals (TebuBio 036SC-108084) in RWPE-1-ARtag cells. Cells were infected with either
NCoRs hRNA or Scramble shRNA particles at an MOI=2. Stable clones were selected with
puromycin at 1µg/ml and cells were kept in same antibiotic condition after selection.
To obtain regulated expression of NCoR, we used the pcDNA4/TO plasmid
(Invitrogen V1020-20). This plasmid contains a hybrid promoter consisting of the
cytomegalovirus immediate-early promoter and two tetracycline operator 2 sites for
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tetracyclin-regulated expression in mammalian cells transfected with the tetracyclin repressor.
The plasmid pcDNA4/TONCoR was constructed by transferring the NCoR cDNA from the
plasmid pGL3 containing the NCoR cDNA to the pcDNA4/TO plasmid. RWPE-1-ARtag cells
were electroporated first with the pCDNA6/TR vector (Invitrogen V1025-20) for 10 seconds
at 250 V and 500 µF (Biorad Gene PulserII). After selection with 5 µg/ml of blasticidin,
RWPE-1-ARtag cells containing the pCDNA6/TR vector were electroporated with either the
pCDNA4/TO or the pCDNA4/TONCoR vectors. Each time, shSc vector (Sigma Aldrich
Shc002) containing puromycin resistance sequence was added in the electroporation mixture
at a ratio 1:10. Cells were selected in keratinocyte medium containing BPE, EGF, 5 µg/ml of
blasticidin and 1 µg/ml of puromycin.
2.2. Cell synchronization and flow cytometry
Cells were synchronized using a double-thymidine-block protocol [15], with a first
block for 24h, a 9h release in presence of 24 µM deoxycytosine, and a second block for 20h.
The final concentration of thymidine used in the block medium was 2 mM. Cells were treated
for 6h with R1881 or ethanol as vehicle at the end of the synchronization process. 
The percentage of cells in each phase of the cell cycle was checked by propidium iodide
(Invitrogen P1304MP) labeling. The fluorescence was measured by flow cytometry. 
To analyze AR translocation in synchronized control and R1881-treated cells, the cells were
fixed with paraformaldehyde at the indicated phases of the cell cycle and stained with both
Hoechst and anti-AR antibody. The number of AR-positive nuclei was counted in 5 different
microscopic fields over 300 cells each.
2.3. RNA extraction and qRT-PCR
RNA was extracted from cells using Trizol Reagent (MRCGene TR118) following
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manufacturer’s instructions. One µg of this RNA was retrotranscribed (Promega M1701). The
cDNA obtained was amplified by qPCR using QuantiTect SYBR® Green PCR Kit (Qiagen
204145). Primers used for quantitative PCR were as follows: TBP (Qiagen QS
MAX0000721); AR (Qiagen QS MAX0073451); NEP (Qiagen QS MAX0048755); Cyr61
(Qiagen QS MAX0003451); ELL2 (Qiagen QS MAX1666910); SGK1 (Qiagen QS
MAX0041293); FKBP5 (Qiagen QS MAX0056714); GAPDH (Qiagen QS MAX1192646);
NCoR (Qiagen QS MAX0065541); CDK4 (Qiagen QS MAX0016107).
2.4. Western Blot
Cells were lysed during 1h in lysis buffer (Tris HCl pH 7.4 50 mM; NaCl 150 mM;
EDTA 5 mM; NP40 0.5% V/V; DTT 0.1 mM and Roche Complete Protease Inhibitor
Cocktail Tablets). After centrifugation at 15000g during 10min the supernatant was collected
and protein concentration determined (Biorad Dc Protein Assay 500-0114). After heat
denaturation SDS-PAGE was performed on a 6% polyacrylamide gel and proteins were
transferred to a nitrocellulose membrane (Hybond Amersham Biosciences). Equal loading was
checked by Ponceau red staining. The membrane was incubated with a monoclonal anti-AR
antibody (Santa Cruz Biotechnology AR (441) sc-7305) and a secondary anti-mouse IgG
antibody coupled to peroxidase (Promega anti-mouse IgG HRP W402B). AR was visualized
by autoradiography.
2.5. Chromatin binding analyses by UV induced crosslinking.
Twenty millions RWPE-1-ARtag cells were used to perform ChIP experiments. Cells
were recovered at each time point following synchronization by scraping in cold PBS. To
crosslink protein-DNA complexes, cells were irradiated with a laser as previously described
[16]. 
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For irradiation of the RWPE-1-ARtag cells with the UV laser, we have used a specially
designed UV laser device that allowed the cells to be irradiated with a single 10 nanoseconds
pulse (see supplementary figures S5 A and B for detailed description of the UV laser device
and protocol). As expected, no induction of covalent AR-DNA adducts was detected in the
control non-irradiated samples (Supplementary figure S5 C).
Cells were kept in cold PBS at a concentration of 2.5.106/ml and circulated through
laminar flow quartz cell by a peristaltic pump (2 ml/min) and the crosslinking was performed
by irradiating at 0.2 J/cm2 with the fourth harmonics generation of a Surelite II Nd:YAG laser
(?=266 nm) at a repetition rate of 10 Hz (see supplementary Figure S5 A and B). The
irradiation geometry and parameters were chosen in a way to irradiate each 3.5 ?l of cell
suspension by a single laser pulse. After centrifugation, cell pellets were resuspended in lysis
buffer (Hepes 50 mM; EDTA 1mM; NaCl 150 mM; Glycerol 5%; Triton X-100 1% and
Roche Complete Protease Inhibitor Cocktail Tablets). After 10 minutes of lysis and further
centrifugation, nuclei were resuspended in RIPA buffer (Tris pH 8 10 mM; EDTA 1 mM
NaCl 150 mM; Glycerol 5%; Nadeoxycholate 0.1%; SDS 0.03%; Triton X-100 1% and Roche
Complete Protease Inhibitor Cocktail Tablets). Chromatin was shared into small fragments by
ultrasounds (Bioruptor, Diagenode) in order to obtain DNA fragments of size between 500
and 1000 bp (not shown). After centrifugation at 15000g for 10 minutes, the supernatant was
collected and 200 µl of SBB 10X (1.5 M KCl; 300 mM Tris; 20 mM EDTA; Triton X-100
0.1%) was added. Forty µl streptavidin Beads (Dynal M-280, Invitrogen 11205D) and blocker
mixtures (yeast tRNA 100 µg/ml; BSA 200 µg/ml) were added and let for over-night
incubation at 4°C with ARtag/chromatin complexes. Since the COOH-terminus of AR was
fused to the SBP peptide the AR-DNA complexes were pelleted using magnetic beads coated
with streptavidin. The beads were then washed 4 times with SBB containing 300 mM KCl, 50
µg/ml yeast tRNA and 100µg/ml BSA and one time with SBB 150mM KCl without any
9
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blocker. After 3h reverse crosslinking at 55°C in digestion buffer (Tris pH 8 10 mM; EDTA 1
mM; SDS 0.7%; Proteinase K 100 µg/ml), DNA was purified by phenol/chlorophorm
extraction. The quantity of DNA was measured by fluorescence (Invitrogen Quantitect
Picogreen dsDNA assay Kit P7589).
To ascertain that this cell cycle dependent identification of AR direct binding would
not reflect some preferential accessibility of the SBP-peptide tag of AR at G1 phase we
performed the same experiment but instead of streptavidin we used anti-AR antibody to
immunoprecipitate the covalent AR-DNA complexes. We obtained the same cyclic pattern of
binding of the AR, thus excluding any technical artifacts (data not shown).
To recover chromatin-RNA polymerase II complexes, 20.106 synchronized RWPE-1-
ARtag cells were processed as for AR following UV laser crosslinking. Four µg of anti-RNA
polymerase II antibody (Upstate CTD4H8) and 40 µl of Protein A Magnetic Beads (Invitrogen
10002D) were used to recover protein-DNA complexes. Wash conditions, elution of DNA
complexes and DNA analysis were the same as for AR.
2.6. Chromatin binding analyzes by formaldehyde- induced crosslinking.
Formaldehyde-induced crosslinking was performed as previously described [13,17]. 
ReChIP experiment was done as described by [18] with some modifications. Fourty
millions synchronized RWPE-1-ARtag cells were lysed in lysis buffer (Hepes 50 mM; EDTA 1
mM; NaCl 150 mM; Glycerol 5%; Triton X-100 1% and Roche Complete Protease Inhibitor
Cocktail Tablets). After 10 minutes of lysis and centrifugation, nuclei were resuspended in
RIPA buffer (Tris pH 8 10 mM; EDTA 1 mM NaCl 150 mM; Glycerol 5%; Nadeoxycholate
0.1%; SDS 1%; Triton X-100 1% and Roche Complete Protease Inhibitor Cocktail Tablets).
Chromatin was shared into small fragments by ultrasounds (Bioruptor, Diagenode). Cell
lysates were centrifuged for 10 minutes at 4°C at 15000rpm. The first immunoprecipitation
10
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was carried out in the presence of 8 µg of anti-NCoR (Santacruz sc-8994) and 80 µl of Protein
A beads (Invitrogen 10002D). Complexes were washed with RIPA buffer containing 300 mM
NaCl and eluted with 10 mM DTT for 30 minutes at 37°C. Recovered complexes were diluted
50 times in Re-ChIP buffer (1% triton X-100; 2 mM EDTA; 150 mM NaCl; 20 mM Tris pH
8). The second immunoprecipitation was performed in presence of 20 µg of anti-AR antibody
(Upstate PG-21) and 80 µl of Protein A beads (Invitrogen 10002D). After 3 washes with Re-
ChIP buffer containing 300 mM NaCl, protein-DNA complexes were de-crosslinked in TE
buffer containing 0.7% SDS and 100 µg/ml of proteinase K for 4 hours at 55°C. DNA was
purified by phenol/chloroform extraction and analyzed by qPCR after picogreen quantification
(Invitrogen Quantitect Picogreen dsDNA assay Kit P7589).
2.7. qPCR following ChIP and primer sequences.
For quantitative PCR, 5 ng of input DNA or ChIP DNA were used. The qPCR
reactions were performed with different quantities of total DNA. Relative fold changes did not
change between different starting DNA quantities, suggesting the linearity of the amplification
(data not shown).
The following primers were used:
ARBS3.12 S: GCAGCCTACGAAAGTCCATC 
ARBS3.12 AS: ACCCAGAGTTGGAACACAAAG 
CYR61 ARE S: TTATCTTCAAGCTGCCTCACC 
CYR61 ARE AS: GACTGGCTGAACCTCTTAGGC 
ELL2 ARE S: CCCTTGGAGTTAGCCACAAC 
ELL2 ARE AS: AATGGAGCAGTGTGCATGAG 
FKBP5 ARE S: ACCCTCCCAGGAAGAATTATG 
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FKBP ARE AS: CCTTAGATGAGCGGTAGAGAGG 
SGK ARE S: AGGGTTTTCAGGTGGGACAGAG 
SGK ARE AS: TGAGGAGGTAACAAGCGAAGG 
NEP AREII S: TTATGGTGGTTGGGTTTACAC 
NEP AREII AS: GGGACAAAATGTCCTGTGC 
XBP S: TCTGGAAAGCTCTCGGTTTG 
XBP AS: AATCCCTGGCCAAAGGTACT 
CDK4 S: ATGCAGACAGGCTGAAAGAC 
CDK4 AS: AACTCCCGGCTGAAGGATT 
NEP ARE -2 kb S: GGAGTCTCGCTCTGTC 
NEP ARE -2 kb AS: GGAGAATGGCTTGAACC 
NEP ARE +2 kb S: CCAATGGCATTCAGTG 
NEP ARE +2 kb AS: CGTAGGAAGGCCTTGAGG 
CYR ARE -2 kb S: GGGAGTTAGGAATGCTGG 
CYR ARE -2 kb AS: GGGCATCCATATCCC 
CYR ARE +2 kb S: CTTACCCCGTCTCCTGC 
CYR ARE +2 kb AS: GGGTTGGAAGTCCGAG
2.8. Flow Cytometry.
Dual labeling of proteins and DNA on flow cytometry was performed as described
previously [9]. For NCoR labeling, 1/50 dilution of polyclonal anti-NCoR antibody was used
(Santa Cruz Biotechnology NCoR sc-8994) and for phospho-histone H3 labeling, 1/500
dilution of monoclonal anti-phospho-histone H3 was used (AbCam 14955). Cell pellets were
incubated with either FITC conjugated anti-mouse IgG (Jackson 715096151) or anti-rabbit
IgG (Jackson 718096152) antibodies. Data were analyzed using a FACSCALIBUR 4C
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Cytometer (Becton Dickinson).   
3. Results
3.1. Establishment of a stable RWPE-1 prostate cell line expressing AR.
The aim of this work was to investigate the molecular mechanisms of the control of
expression of AR target genes in prostate cells. Several tumor-derived adult prostatic
epithelial cell lines (including LNCaP, VCaP and LAPC-4) have been established and
described in the literature [19]. Although most of the described cell lines are sensitive to
androgens, AR is mutated in many of these cells, and the tumorigenic phenotype of the cells
might alter transcriptional response to androgens.  
With this in mind we choose the non-tumorigenic immortalized prostate cells RWPE-
1 as a model. These cells have been immortalized by infection with HPV18 [20]. Like many
non-tumorigenic immortalized prostate cells described so far [17,21,22], these cells express
barely detectable amounts of AR protein. To overcome this limitation we established a stable
cell line RWPE-1-ARtag that constitutively expresses an exogenous AR. The COOH-terminus
of AR was fused to the SBP and CBP peptides and the ARtag cDNA sequence was stably
introduced into the cell genome via a lentiviral vector to insert a low number of proviral
copies. The cell model we established was similar to the one used by Bolton et al. to study
binding of AR to chromatin [17]. 
To analyze the response to androgens in these cells we followed the expression of a
panel of known AR target genes. The chosen genes were NEP, CYR61, ELL2, FKBP5 and
SGK [17,23-26]. These cells also express the NKX3.1 gene under androgen stimulation but
this gene was not included in the panel of studied genes. The nature of the proteins encoded
by these genes, and the structure and position of the ARE binding sites within the respective
genes are presented in table 1 of supplementary data.
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In contrast to RWPE-1 cells which did not show any enhancement of AR target gene
expression upon androgen stimulation, the androgen response in RWPE-1-ARtag cells was
detected as soon as 3 hours after addition of R1881 with for some of the genes a particularly
high transcriptional activation (>10, data not shown). 
3.2. Cell-cycle-dependent Expression of AR Target Genes in RWPE-1-ARtag Cells.
To investigate the response to androgens during the cell cycle, we performed a cell
cycle synchronization of the RWPE-1-ARtag cells using the double thymidine block technique
[15]. The protocol scheme is presented in Figure 1A. At each step of the synchronization
procedure the percentage of cells at the different phases of the cycle was assessed by FACS
analysis. The data showed that the double thymidine block resulted in a highly efficient
synchronization of the RWPE-1-ARtag cells. Indeed, more than 60% of the cells were in S
phase at point T0, close to 70% in G2/M at time T1 and more than 80% in G1 at time T2
(Figure 1 B). After refeeding with normal medium at time T3, the cells entered into a second
cell cycle. Six hours after refeeding (time T4), 40% of the cells were in both S and G1 phases
and after 26 hours (time T5) more than 80% of cells reached again the G1 phase (Figure 1 B).
Treatment with 1 nM of R1881 for 6 hours had no effect on the synchronization of the cells
(data not shown). For simplicity we will further refer T0, T1, T2, T4 and T5 to as Smax,
G2/Mmax, G1max, G1/S and G1max-2, respectively. 
A Western blot analysis showed that the level of expression of AR was constant
during the cell cycle (Figure 1 C). We also found that the translocation of AR into the nucleus
was strongly enhanced by androgen stimulation and that the level of the translocated AR
remained unchanged at the different phases of the cell cycle (Figure 1 D). Thus, this
synchronization procedure of the RWPE-1-ARtag cells offered a good model to study how AR-
target gene expression is regulated during the cell cycle. The light bands observed under the
14
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major band for AR might represent minor cleavage or degradation products.
Analysis of the expression of AR-target genes in response to R1881 in synchronized
cells showed that all studied target genes exhibited a cell cycle dependent expression which
peaked at the G1 phase (Figure 2). As controls we analyzed the expression of the non AR-
target genes GAPDH and CDK4. As expected, the mRNA levels of these genes did not
change significantly during the cell cycle in response to R1881. Similarly, the level of AR
mRNA did not vary during the cycle since AR was constitutively expressed from the
retroviral vector. We conclude that in response to androgen stimulation the expression of AR-
target genes (as assessed by their mRNA levels) takes place mainly in the G1 phase of the cell
cycle. 
3.3. Cell cycle dependent expression of NCoR in RWPE-1-ARtag cells
The transcriptional activity of AR is regulated through interactions with co-activator
and co-repressor partner proteins [27]. We hypothesized that the cyclic expression of AR-
target genes might be regulated through cell cycle dependent expression and/or activity of
such partners. Through screening several AR co-factors for their expression in synchronized
cells by RT-qPCR we found that the co-repressor NCoR exhibited an interesting pattern of
expression. Its mRNA level was high in S and G2/M phases and showed a sharp decrease in
G1 (Figure 3 A). In agreement with this finding, the protein was detected predominantly
during the S phase and at a much lower but still detectable level during the G2/M phase
(Figure 3 B). 
We further demonstrated that this S phase specific NCoR expression was not an
artifact induced by the synchronization procedure by analyzing the expression of NCoR in
non-synchronized cells by FACS. As a control we have studied the cell cycle dependent
phosphorylation of histone H3. Histone H3 is phosphorylated at the G2/M phase and, as
15
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mitosis proceeds, it is dephosphorylated at anaphase [28]. From the FACS analysis presented
in figure 3 C and supplementary data S2 we estimated that close to 73 % of cells in S phase
were positive for NCoR. In the G1 phase the fraction of NCoR positive cells represented less
than 10%. R1881 treatment did not alter this expression pattern (data not shown). This
pattern of expression was not specific to the modified RWPE-1-ARtag cells. Indeed the
original RWPE-1 cells as well as their Ki-ras-transformed malignant counterpart RWPE-2
(14) showed the same preferential expression of NCoR during the S and G2/M phases
(supplementary figure S1). Furthermore, we also found that this cell cycle dependent
expression of NCoR is preserved in other prostate cell lines (supplementary data S2). Indeed,
in PC3 and LNCaP cells, a major expression of NCoR was observed in cells in S phase. These
data clearly demonstrate that cell cycle dependent expression of NCoR is not restricted to the
RWPE-1 cellular model.
Taken together, all these data demonstrate that NCoR expression is regulated during
the cell cycle and peaks at the S and early G2/M phases. 
3.4. NCoR binds to chromatin only during the S Phase of the cell cycle.
The above data suggest that the cyclic expression of NCoR could be associated with
the regulation of the expression of AR target genes during the cell cycle. To test this
assumption we have analyzed the NCoR binding pattern to the chromatin of AR-target genes
during the cell cycle using formaldehyde-induced crosslinking followed by chromatin
immunoprecipitation (ChIP). As seen in Figure 4, NCoR was associated with the ARE in the
chromatin of all tested AR-target genes only during the S phase in both the presence and
absence of R1881. Surprisingly when tested on the CYR61 and NEP genes, NCoR was also
found associated with sites located 2kb upstream and downstream from the ARE. No NCoR
16
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association was found on the androgen-independent XBP gene.
3.5. Analysis of AR binding to AR-target genes within the chromatin
AR was constitutively expressed all along the cell cycle in RWPE-1-ARtag cells
(Figure 1). Bearing this in mind, we next asked whether AR was also constitutively bound to
its target genes throughout the cell cycle and if bound, whether its binding is productive in
term of transcription. To address this question we used two different crosslinking techniques,
namely formaldehyde and UV laser protein-DNA crosslinking that distinguish between direct
and indirect binding to chromatin DNA. 
The widely used formaldehyde crosslinking technique reveals protein binding to
chromatin DNA either as a direct interaction with DNA or as an indirect interaction though
protein-protein induced crosslinking [29]. In contrast the UV laser induced crosslinking
technique reveals only direct protein-DNA interactions. Indeed one of the most efficient
photoreaction induced by UV laser irradiation of nucleoprotein complexes is the generation of
covalent protein-DNA adducts [30]. Since UV light is a "zero length crosslinking agent" the
protein-DNA crosslinking is achieved only between the DNA bases and the amino acids
residues that are in direct contact [30] . In addition, no protein-protein crosslink is induced in
these conditions [16,31,32]. The UV laser crosslinking technique was successfully applied to
study the direct binding of histone and several transcription factors to DNA both in vitro and
in vivo [33-38] and to map transcription factor-DNA contact points [39].
Using the formaldehyde-induced crosslinking we then analyzed the interaction of AR
with the ARE of NEP, CYR61, FKBP5, ELL2, ARBS3.12 and SGK genes. We also analyzed
binding to sequences located 2 kb upstream and downstream from the ARE of NEP and
CYR61. The promoter regions of XBP and CDK4 genes that are not AR-targets were used as
negative controls. The analysis was conducted at various phases of the cell cycle on
17
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synchronized RWPE-1-ARtag cells. All the data are presented in figure 5. Upon R1881
treatment a very high enrichment of AR associated with the ARE of all analyzed AR-target
genes was found mostly at the G1 and S phases. A much lower, but still significant binding,
was found at the G2/M phase. No AR binding to the chromatin of CDK4 and XBP genes was
detected at any phase of the cell cycle. These data illustrate that in RWPE-1-ARtag cells AR is
associated with the ARE during both G1 and S phase. No significant interaction of AR with
the chromatin was observed 2kb outside of the ARE on the NEP and CYR61 genes.
Using the UV laser crosslinking technique we could observe that the direct binding of
AR was clearly enhanced by androgen stimulation and took place mainly at the G1 phase on
the ARE of all AR-target genes (Figure 6). A lower binding in the G1/S phase might reflect a
smaller fraction of cells in G1 in these samples. As expected, AR did not bind to regions
located 2Kb down and upstream from the respective ARE sequences of the two genes Cyr61
and NEP. No binding of AR was detected on the non-AR target genes CDK4 and XBP. 
From all these observations we conclude that the direct binding of AR to its cognate
sequences occurs mostly during the G1 phase whereas indirect binding to the same sites could
also take place during the S phase. 
3.6. Direct G1 phase binding of AR correlates with the transcriptional activation of its
target genes
To test whether AR binding in G1 takes place on transcriptionally active target genes
we analyzed the direct binding of RNA polymerase II using the UV laser-crosslinking
technique. As shown in Figure 7, in the presence of androgens, RNA polymerase II was found
directly bound to the ARE of all tested AR target genes only in G1. On the CDK4 gene
(whose expression is independent of the cell cycle) RNA polymerase II was found to bind to
the promoter region independently of androgen stimulation and nearly at the same level at
18
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each phase of the cell cycle.  As expected no binding of RNA polymerase II was detected on
the non-induced XBP gene. Therefore, these data demonstrate a strong correlation between
direct binding of AR and RNA polymerase II to the control regions of AR-target genes during
the G1 phase of the cell cycle and the specific expression of these genes during this phase. 
3.7. NCoR interacts with AR on ARE during the S phase of the cell cycle.
To further characterize cell cycle dependent regulation of AR by NCoR, a sequential
ChIP experiment was performed to analyze the interaction between NCoR and AR during the
cell cycle. The first immunoprecipitation was carried out using an anti-NCoR antibody. The
eluted material was next immunoprecipitated with an anti-AR antibody. As shown in Figure 8
AR and NCoR interacted to each other on the ARE of the tested NEP, CYR61 and FKBP5
genes in the presence of R1881 during the S phase. Note that no interaction of NCoR and AR
was detected 2kb outside of ARE. Identical results were obtained when the order of the two
immunoprecipitations was inverted (Supplementary Figure S3). These data showed that in S
phase NCoR and AR interact between each other and with the DNA in the chromatin of AR-
target genes.
3.8. Alterations of the cell cycle NCoR expression affect the cyclic expression of AR
target genes. 
To confirm that NCoR could be involved in the cell cycle regulation of AR-target
genes we stably knocked it down using virally expressed specific NCoR-shRNA. The effects
were analyzed in synchronized cells. In NCoR-shRNA-infected RWPE-1-ARtag cells the level
of NCoR mRNA was reduced by 65 % and the level of the protein was undetectable (Figure 9
A). 
Data presented in Figure 9 B show that in the presence of R1881 NCoR-shRNA
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induced a re-expression of the NEP, SGK and FKBP5 genes during the S phase in addition to
the expression during the G1 phase. The knockdown of NCoR had only a marginal effect on
the expression level of CDK4, GAPDH and AR genes. Similar data were obtained in cells
transfected with NCoR-siRNA (supplementary figure S4). These data strongly suggest that
NCoR is involved in the down regulation of AR-target genes during the S phase.
To check whether this re-expression in S phase did indeed correlate with the direct
binding of AR to the target ARE, we analyzed the binding of AR on the NEP, SGK and
FKBP5 ARE using the UV Laser crosslinking technique. As shown in Figure 9 C the down-
regulation of NCoR was associated with a direct binding of AR to the ARE during both the S
and G1 phases. No change in S phase was observed for the control genes CDK4 and GAPDH
(not shown). 
To further confirm the role of NCoR in the cell cycle expression of AR target genes,
we used an alternative strategy allowing the permanent expression of the protein during the
cell cycle. We first established an RWPE-1-ARtag cell lines containing a stably integrated
NCoR gene under the control of the doxycycline (Dox) inducible promoter (RWPE-1-ARtag-
TONCoR cell line). As shown in Figure 10 A, upon Dox treatment NCoR mRNA and protein
levels were up regulated ~2 fold in both the G1 and S phases as compared to non-treated cells
(or cell containing an empty vector, data not shown). As shown in figure 10 B the treatment
with Dox affected slightly the expression of AR and had, as expected, no effect on the
expression of the CDK4 gene. In contrast the expression of the tested AR-target genes NEP
and CYR61 was abrogated during the G1 phase.
Taken altogether these data identify NCoR as the major actor restricting activation of
the expression of AR-target genes specifically to the G1 phase in the RWPE-1-ARtag cells.
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4. Discussion
The aim of this work was to investigate the pattern of expression of AR-target genes in a
prostate immortalized cell line carrying a constitutively expressed exogenous AR. We found
that in these cells, androgen-induced expression of AR-target genes assessed from mRNA
expression took place only during the G1 phase of the cell cycle. Searching factors that might
control a cell cycle specific regulation of transcription we found that the co-repressor NCoR
was expressed specifically during the S and early G2/M phases. This has led us to carry out
experiments which demonstrated that NCoR should be involved in the G1 phase specific
expression of AR-target genes. Indeed, down-regulation of NCoR expression by shRNA or
siRNA resulted in a re-expression of AR-target genes in S phase (where they are otherwise
silent). In contrast, the constitutive expression of NCoR during the cell cycle induced a
repression of AR-target genes expression during the G1 phase.
Another original finding of this work was brought from the use of two alternative
techniques to study the binding of these proteins to chromatin DNA, namely formaldehyde-
and UV laser-crosslinking techniques. The widely-used formaldehyde crosslinking technique
induces protein-protein as well as protein-DNA covalent crosslinking and thus reveals both
direct and indirect binding of proteins to DNA [29]. The UV laser-induced crosslinking
technique induces only protein-DNA crosslinking and thus reflects exclusively direct protein
binding to chromatin DNA [16,32,40]. 
The quantities of the total DNA recovered from ChIP performed after respectively
formaldehyde- or UV laser-induced crosslinking were comparable (data not shown).
However, both techniques induced different enrichments of complexed chromatin. This
difference was probably due to the lower efficiency of crosslinking induced by UV laser
irradiation as compared to formaldehyde. Noteworthy, under the conditions of UV irradiation
roughly 6-8% of the histones are found covalently crosslinked to DNA [38]. Alternatively the
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higher enrichment of bound chromatin after formaldehyde-induced crosslinking might reflect
the consequences of indirect binding through protein-protein interactions [41].
By using these two techniques we have demonstrated that: (i) AR bound directly to
target gene DNA only at G1 phase and, (ii) AR appeared to bind indirectly to chromatin
during S phase of the cell cycle. Noteworthy, the binding at G1 correlated with the direct
binding of polymerase II to target genes exclusively during this phase which strongly suggests
that in G1 expression of AR target genes resulted from AR induced transcriptional activation
through a direct and productive interaction with the DNA of the control regions of these
genes. 
We have also observed a decrease of the expression of AR-target genes during the
G2/M transition. This correlated with a strong decrease of the interaction of AR and
polymerase II with the AR target gene chromatin. As the amount of expressed exogenous AR
was constant during the cell cycle the above effect should reflect the release of AR from the
chromatin during the G2/M phase. Such release was also described for several other
transcription factors and appeared to be associated with chromatin condensation during
mitosis [42].
The formaldehyde-crosslinking technique showed that NCoR protein bound to AR
target genes only during the S phase. As no binding was detected following the UV laser
crosslinking technique (not shown) we conclude that NCoR bound to the chromatin of AR-
target genes in S phase through protein-protein and not direct protein-DNA interactions.
NCoR was found to bind also to the chromatin regions located 2 kb around the ARE which
strongly suggests that binding of NCoR to AR-target genes in not governed by the presence of
the ARE. We assume that in order to act as a repressor, NCoR has to "coat" relatively large
chromatin fragments. This raises the question of how NCoR recognizes and coats the
promoter and surrounding chromatin regions. We cannot give a definitive answer to this
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question, but we can hypothesize that other, yet not identified factors, different from AR,
might "guide" NCoR over the AR-target genes.
We have also found that when abrogating expression of NCoR during the S phase in
shRNA expressing cells, AR can bind again directly and productively to ARE. This suggests
that the binding of NCoR to the chromatin in S phase interferes with the direct interaction of
AR with ARE DNA. We speculate that the constitutive expression of an exogenous AR leads
to its permanent interaction with the chromatin during the whole cell cycle. In S phase NCoR
binds to AR and displaces it from its direct interaction to the ARE DNA. In the absence of
NCoR in G1 phase, AR is again able to directly interact with DNA and to drive transcriptional
activation. 
We note that this mechanism of regulation would operate in our experimental system,
i.e. in the prostate cell line which constitutively expressed AR. Such mechanism may not,
however, operate, in genetically non-modified or other prostate cell lines, since in such cell
lines AR is not expressed during the whole cell cycle. For example, in prostate tumor cell
lines, Litvinov et al. showed that endogenous AR is ubiquitinylated and degraded during the
M phase [9]. The question remains to know whether this cell cycle regulation of AR target
genes by androgens would exist in prostate cancer cells expressing an endogenous AR. We
could not address this question because we have been unable to perform a reliable and
repetitive synchronization of tumor prostate cell lines using the thymidine block protocol used
here. This defect might be due to the tumor nature of the cells which there from exhibit a
completely deregulated cell cycle control. Nonetheless, the RWPE-1-ARtag cell line we
developed was very useful to identify a cell cycle regulated expression of NCoR and to dissect
the potential role of NCoR in the regulation of expression of AR target genes. In this context,
it is worthwhile to stress that NCoR appears to regulate the cell cycle expression of AR target
genes even in the large excess of AR. It is interesting to notice that although the mRNA of
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NCoR was still detectable during the G2/M phase its protein amount was globally deeply
decreased. FACS distribution of NCoR positive cells showed that this decrease was even
more pronounced in cells in late G2/M phase. This might suggest that NCoR protein
expression might follow a specific post-transcriptional regulation during late G2/M phase.
In conclusion these data open thus new considerations on the roles and mechanisms of
action of NCoR in prostate cells.
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Figure 1: Synchronization of RWPE-1-AR
tag
 cells using double thymidine block.  
(A) Schematics of the RWPE-1-AR
tag
 synchronization protocol by double thymidine 
block. (B) Flow cytometry measurements of the percentage of cells at distinct phases 
of the cell cycle. Cells were harvested at the indicated time points after addition of 
thymidine. (C) Western blot analysis of the expressed AR at different phases of the 
cell cycle. Slight bands below the AR band are interpreted as degradation products. 
(D) Translocation of AR into the nucleus upon R1881 treatment in synchronized 
RWPE-1-AR
tag
 cells. Histograms show the percentage of AR-positive nuclei in the 
presence (+) and in the absence (-) of R1881.   
 
Figure 2: Treatment with R1881 results in specific expression of AR target genes 
mRNA in synchronized RWPE-1-AR
tag
 cells at G1 phase of the cell cycle.  
Total RNA was isolated from control cells and cells treated for 6 hours with R1881-
treated at the indicated phases of the cell cycle and used for RT-qPCR. CDK4 and 
GAPDH genes were used as negative controls. Means of 3 independent experiments 
are shown. Data represent the mean +/- SD from 3 independent experiments.  
 
Figure 3:  Cell cycle dependant expression of NCoR.  
(A) NCoR mRNA expression in synchronized RWPE-1-AR
tag
 cells. One µg of total 
RNA was reverse transcribed from each phases of the cell cycle. NCoR expression 
was quantified by RT-qPCR using specific primers. Data represent the mean +/- SD 
from 3 independent experiments. (B) Western blot analysis of the expression of 
NCoR protein in synchronized RWPE-1-AR
tag
 cells. The blot was revealed with an 
anti-NCoR specific antibody (upper panel). An anti-actin antibody was used for 
testing the equal loading (lower panel). (C) Dual-parameter FACS analysis of 
proliferating RWPE-1-AR
tag
 cells. One million exponentially growing cells were 
fixed and labelled either with an anti-phospho-histone H3 or an anti-NCoR antibody 
and propidium iodide as described in material and methods. As background control to 
position phases of the cell cycle, cells were labelled only with propidium iodide and 
FITC conjugated antibody. 
 
Figure 4: NCoR is associated with ARE and surrounding chromatin regions only 
during the S phase.  
ChIP were carried out on synchronized RWPE-1-AR
tag
 cells after crosslinking with 
Figure
Page 32 of 44
Ac
ce
pte
d M
an
us
cri
pt
formaldehyde using a specific anti-NCoR antibody. The data were normalized relative 
to DNA precipitated with a non-specific antibody (IgG). Means of 3 different 
experiments are presented. 
 
Figure 5: Interaction of AR with chromatin following formaldehyde-induced 
crosslinking.  
Control cells and cells treated with R1881 (10
-9
M) for 6 hours were harvested at the 
indicated phases of the cell cycle and crosslinked with formaldehyde. ChIP were 
further performed using an anti-AR antibody. Precipitated DNA was amplified by 
using ARE specific primers and primers for DNA sequences located at 2kb either 
upstream or downstream from the ARE  for both NEP and CYR61 AR target genes. 
The data were normalized relative to DNA precipitated with non-specific antibody 
(IgG). The bottom two panels show the AR fold enrichment for non-AR target gene 
sequences (XBP and CDK4, negative controls). Data represent the mean +/- SD from 
3 independent experiments. Note that the ordinate scales are different between the 
tested genes. 
 
Figure 6: Interaction of AR with chromatin following UV laser induced crosslinking. 
Cells were harvested at the indicated phases of the cell cycle and irradiated with the 
UV laser as described in Materials and Methods. The crosslinked AR complexes were 
isolated using streptavidin-coated beads. Precipitated DNA was then amplified using 
ARE specific primers and primers for DNA sequences located at 2kb either upstream 
downstream to the ARE for both NEP and CYR61 genes. Results are presented as 
fold enrichments relative to RWPE-1-pWR cells not expressing the tagged androgen 
receptor (pWR). Data represent the mean +/- SD from 5 independent experiments. 
 
Figure 7: Binding of RNA polymerase II to AR target genes in the chromatin. 
The experiment was carried out as described in figure 6 except that  RNA polymerase 
II–DNA complexes were recovered with a specific antibody against the enzyme. The 
fold enrichment for each gene was normalized relative to DNA precipitated with non-
specific antibody (IgG). Data represent the mean +/- SD from 3 independent 
experiments. 
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Figure 8:  Analysis of the interaction between NCoR and AR on the chromatin during 
the cell cycle. 
Synchronized RWPE-1-AR
tag
 cells were treated with formaldehyde and the covalent 
NCoR-chromatin complexes were precipitated with anti-NCoR antibody. After 
elution, the complexes were re-immunoprecipitated with anti-AR antibodies. The data 
represent the fold enrichment relative to the control re-ChIP using the non-specific 
antibody combination IgG-IgG. AR-IgG and IgG-NCoR correspond to additional 
controls where antibodies against AR or NCoR were respectively replaced by control 
IgG. The sequential ChIP were performed by using the pooled material from two 
independent ChIP experiments. Note that ordinate scales are different between tested 
genes. 
 
 
Figure 9: Knock-down of NCoR affects cell cycle dependent expression of AR target 
genes in synchronized RWPE-1-AR
tag
 cells.  
(A): expression of NCoR mRNA and protein in cells treated with respectively shScrbl 
and shNCoR shRNA.  
(B): Expression of AR target genes and control genes in synchronized RWPE-1-AR
tag
 
cells expressing scramble shRNA or NCoR shRNA.  
(C): Binding of AR to chromatin in genes in synchronized RWPE-1-AR
tag
 cells 
expressing scramble shRNA or NCoR shRNA. Binding was analysed following UV 
laser induced crosslinking similarly to experiments in figure 6. 
All data represent the mean +/- SD from 3 independent experiments. 
 
Figure 10: Overexpression of NCoR during the G1 phase abrogates expression of AR 
target genes. 
 (A): Expression of NCoR mRNA and protein in control cells and cells treated with 
doxycyclin. 
(B):  Expression of AR target genes and control genes in synchronized RWPE-1-
AR
tag
 control cells and cells overexpression NCoR following induction with 
doxycyclin. 
 Doxycycline was added to the medium to induce overexpression of NCoR and the 
cells were treated with R1881 for 6 hours. Cells at the indicated phase of the cell 
cycle were then processed for mRNA expression. Data represent the mean +/- SD 
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